Related Experiment Video
Updated: Jun 13, 2025

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
Published on: September 28, 2022
Epstein Barr virus: A cellular hijacker in cancer
Moyed Alsaadawe1, Bakeel A Radman2, Jingyi Long3
1Department of Laboratory Medicine, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China; The Third School of Clinical Medicine, Southern Medical University, Guangzhou, China; Al-Qadisiyah Education Directorate, Ministry of Education, Al-Qadisiyah, Iraq.
Epstein-Barr Virus (EBV) drives cancers like lymphoma and gastric carcinoma by disrupting cell growth. Ongoing research focuses on vaccines and targeted therapies to combat these EBV-associated malignancies.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Epstein-Barr Virus (EBV), a common gammaherpesvirus, infects over 90% of adults worldwide.
- EBV establishes lifelong latent infections in B cells, epithelial cells, and NK/T cells.
- The virus is implicated in various cancers, including Burkitt's lymphoma, nasopharyngeal carcinoma, Hodgkin's lymphoma, and EBV-associated gastric carcinoma.
Purpose of the Study:
- To review the role of EBV in oncogenesis.
- To highlight challenges in diagnosing latent EBV infections and developing targeted therapies.
- To summarize current research directions for combating EBV-associated malignancies.
Main Methods:
- Literature review of studies on EBV and cancer.
- Analysis of EBV's molecular mechanisms in cancer development, including latent proteins (EBNA-1, LMP1, LMP2A).
- Examination of EBV's role in tumor progression and immune evasion.
Main Results:
- EBV contributes to cancer by inhibiting apoptosis and promoting cell proliferation via latent proteins.
- EBV's switch between latent and lytic phases accelerates tumor progression, particularly in nasopharyngeal carcinoma.
- Difficulties persist in detecting latent EBV infections and developing effective targeted treatments.
Conclusions:
- Further research into EBV's interaction with immune evasion and cancer formation is crucial.
- Development of vaccines, improved diagnostics, and targeted therapies are key to managing EBV-associated cancers.
- Enhanced understanding and therapeutic strategies are needed to reduce the global burden of EBV-related malignancies.
More Related Videos
Related Concept Videos
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Mitogens and the Cell Cycle
Induced Pluripotent Stem Cells
Somatic...
Cancers Originate from Somatic Mutations in a Single Cell

